orforglipron (Foundayo)events and moves- 14 Nov 2026 Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale own move -0.3%, next session +0.3%
- 9 Nov 2026 Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss own move +2.4%, next session +1.1%
- 1 Oct 2026 Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease own move +0.7%, next session -0.6%
- 30 Sep 2026 Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study own move -1.0%, next session +0.7%
- 29 Sep 2026 Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison own move +0.3%, next session -1.0%
- 21 Sep 2026 Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 own move +0.7%, next session -0.1%
- 15 Sep 2026 Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health own move -0.1%, next session +0.1%
- 10 Aug 2026 MHRA approval: Weight management in adults (BMI >=30, or 27-30 with a weight-related comorbidity) and glycaemic control in insufficiently controlled type 2 diabetes own move +2.2%, next session -1.1%
- 25 Jun 2026 What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management own move -0.6%, next session +4.1%
- 8 Jun 2026 Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials own move +1.8%, next session -1.6%
- 7 Jun 2026 Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause own move +1.8%, next session -1.6%
- 28 May 2026 Foundayo and Zepbound now covered for millions of Americans own move +2.6%, next session -1.0%
- 28 May 2026 Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care own move +2.6%, next session -1.0%
- 12 May 2026 Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials own move +0.4%, next session +2.0%
- 16 Apr 2026 ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health own move +0.7%, next session +1.1%
| 25 | 23% |
Donanemab (Kisunla)events and moves- 9 Jul 2026 Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment own move +0.2%, next session -1.5%
- 30 Apr 2026 Health Canada approval: Alzheimer's disease (Notice of Compliance, new active substance, Eli Lilly Canada) own move +7.6%, next session +3.6%
- 25 Sep 2025 Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease own move -2.0%, next session +0.4%
- 24 Sep 2025 EC/EMA approval: Early Alzheimer's disease (mild cognitive impairment and mild dementia) in adults who have one or no copy of ApoE4 own move -0.3%, next session -2.0%
- 30 Jul 2025 Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease own move -0.2%, next session +0.2%
- 25 Jul 2025 Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease own move +0.4%, next session +0.3%
- 9 Jul 2025 FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease own move +0.8%, next session -0.1%
- 21 May 2025 Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease own move -0.6%, next session -0.6%
- 17 Dec 2024 Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease own move +0.0%, next session -0.4%
- 2024-12 NMPA approval: Early symptomatic Alzheimer's disease in adults (mild cognitive impairment and mild dementia with confirmed amyloid pathology) own move +0.7%, next session +1.9%
- 29 Oct 2024 Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study own move +1.2%, next session -6.1%
- 23 Oct 2024 Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers own move -0.2%, next session -0.7%
- 2024-10 MHRA approval: Mild cognitive impairment or mild dementia due to Alzheimer's disease own move +0.4%, next session +0.9%
- 24 Sep 2024 MHLW approval: Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid pathology) own move +0.8%, next session +1.0%
- 24 Sep 2024 Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease own move +0.8%, next session +1.0%
| 15 | 6% |
Pirtobrutinibevents and moves- 2 Oct 2026 Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL own move -0.6%, next session -0.7%
- 2026-09 NMPA approval: Jaypirca (pirtobrutinib) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, all lines of therapy regardless of prior covalent BTK inhibitor treatment own move -0.4%, next session -0.7%
- 26 Jun 2026 Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy own move +4.1%, next session +1.6%
- 14 Jun 2026 Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL own move +0.3%, next session -0.6%
- 2 Jun 2026 Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting own move -0.7%, next session +0.6%
- 13 Apr 2026 Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL own move -1.5%, next session -1.3%
- 9 Dec 2025 Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL own move -0.6%, next session -0.3%
- 7 Dec 2025 Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) own move -0.1%, next session -0.6%
- 3 Dec 2025 U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor own move -1.7%, next session -1.1%
- 24 Nov 2025 Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting own move +0.6%, next session +1.5%
- 8 Sep 2025 Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL own move +1.6%, next session +1.1%
- 29 Jul 2025 Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL own move -5.0%, next session -0.2%
- 28 Feb 2025 Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor own move +0.5%, next session +0.6%
- 9 Dec 2024 Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting own move -3.1%, next session -0.1%
- 5 Nov 2024 Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting own move -0.7%, next session -3.8%
| 15 | 4% |
lebrikizumab (Ebglyss)events and moves- 5 Oct 2026 Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions own move -0.7%, next session +1.4%
- 1 Oct 2026 EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab own move +0.7%, next session -0.6%
- 30 Sep 2026 New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis own move -1.0%, next session +0.7%
- 9 Jun 2026 FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis own move -1.6%, next session +0.4%
- 27 Mar 2026 Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis own move -0.4%, next session +0.6%
- 16 Mar 2026 Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis own move -0.4%, next session -5.0%
- 24 Oct 2025 Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis own move +0.5%, next session -0.1%
- 7 Mar 2025 Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis own move -4.7%, next session -3.5%
- 25 Oct 2024 Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab own move +0.7%, next session +0.2%
- 25 Sep 2024 New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis own move +1.0%, next session -2.0%
- 13 Sep 2024 FDA approval: EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. own move -1.4%, next session -0.7%
- 13 Sep 2024 FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis own move -1.4%, next session -0.7%
| 11 | 3% |
mirikizumab (Omvoh)events and moves- 19 Oct 2026 Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis own move -0.7%, next session +1.1%
- 15 Oct 2026 New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year own move +1.7%, next session +0.7%
- 5 May 2026 Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years own move +1.8%, next session -0.3%
- 19 Feb 2026 Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) own move +0.5%, next session -1.1%
- 11 Feb 2026 NMPA approval: Adults with moderate to severe active Crohn's disease and ulcerative colitis (IV and SC forms) own move -1.5%, next session +2.4%
- 27 Oct 2025 Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis own move -0.1%, next session -0.1%
- 27 Oct 2025 Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis own move -0.1%, next session -0.1%
- 7 Oct 2025 Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis own move -0.2%, next session +0.1%
- 2025-07 Health Canada approval: Adults with moderately to severely active Crohn's disease own move -1.9%, next session +1.4%
- 7 Feb 2025 Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years own move +1.4%, next session -1.0%
- 15 Jan 2025 FDA approval: moderately to severely active Crohn's disease in adults own move -0.2%, next session +1.1%
- 15 Jan 2025 FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease own move -0.2%, next session +1.1%
- 13 Dec 2024 Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease own move +0.9%, next session -0.1%
- 28 Oct 2024 Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease own move +0.2%, next session +1.2%
- 14 Oct 2024 Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease own move -0.8%, next session -0.5%
| 13 | 1% |
retatrutideevents and moves- 14 Nov 2026 Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale own move -0.3%, next session +0.3%
- 12 Nov 2026 Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 own move -0.1%, next session +0.6%
- 5 Nov 2026 Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity own move -1.3%, next session -0.7%
- 28 Oct 2026 Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial own move +0.2%, next session +4.2%
- 29 Sep 2026 Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes own move +0.3%, next session -1.0%
- 15 Sep 2026 Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health own move -0.1%, next session +0.1%
- 12 Aug 2026 Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market own move +0.2%, next session -0.9%
- 23 Jul 2026 Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C own move +0.7%, next session +0.2%
- 6 Jun 2026 Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications own move +1.8%, next session -1.6%
- 28 May 2026 Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care own move +2.6%, next session -1.0%
- 21 May 2026 Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial own move +1.5%, next session +1.1%
- 19 Mar 2026 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes own move +0.3%, next session -0.3%
- 11 Dec 2025 Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial own move +0.6%, next session +1.5%
| 13 | 1% |
Imlunestrant (Inluriyo)events and moves- 13 Oct 2026 Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer own move -0.0%, next session +1.1%
- 18 Sep 2026 FDA approves Inluriyo in combination with Verzenio own move +0.3%, next session +0.7%
- 18 Sep 2026 FDA approval: In combination with abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression after endocrine therapy own move +0.3%, next session +0.7%
- 24 Feb 2026 MHRA approval: Adults with locally advanced or metastatic breast cancer that has progressed after at least one line of hormonal treatment own move -1.1%, next session -1.3%
- 9 Jan 2026 EC (EMA) approval: Locally advanced or metastatic ER-positive, HER2-negative breast cancer with an activating ESR1 mutation (monotherapy) own move -1.5%, next session +1.6%
- 22 Dec 2025 PMDA approval: Treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER 2 )-negative inoperable or recurrent breast cancer with ESR1 mutation that has progressed after endocrine therapy own move +0.2%, next session -0.2%
- 12 Dec 2025 Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer own move +1.5%, next session +2.1%
- 24 Nov 2025 Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium own move +0.6%, next session +1.5%
- 25 Sep 2025 FDA approval: 1 INDICATIONS AND USAGE INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. own move -2.0%, next session +0.4%
- 25 Sep 2025 FDA approval: INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. own move -2.0%, next session +0.4%
- 25 Sep 2025 U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer own move -2.0%, next session +0.4%
- 22 May 2025 Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting own move -0.6%, next session -0.0%
- 11 Dec 2024 Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer own move +0.9%, next session -0.9%
- 1 Nov 2024 Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium own move -1.9%, next session -0.9%
| 11 | 1% |
Tirzepatide (Mounjaro) (Mounjaro)events and moves- 28 Aug 2026 La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 own move +0.1%, next session -1.2%
- 28 Aug 2026 FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes own move +0.1%, next session -1.2%
- 27 Aug 2026 FDA Boxed Warning on Mounjaro (NDA215866) own move +0.0%, next session +0.1%
- 27 Aug 2026 FDA approval: MOUNJARO (tirzepatide): to lower the risk of major adverse cardiovascular events, including cardiovascular death, in adults with type 2 diabetes at high cardiovascular risk (SURPASS-CVOT) own move +0.0%, next session +0.1%
- 28 May 2026 Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care own move +2.6%, next session -1.0%
- 17 Sep 2025 Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes own move -0.8%, next session +0.2%
- 31 Jul 2025 Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease own move +0.2%, next session +2.5%
- 29 May 2025 Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions own move -0.2%, next session +1.9%
- 20 Dec 2024 FDA approves Zepbound for obstructive sleep apnea in adults with obesity own move +0.1%, next session +3.2%
| 7 | shown from 8 days |
ixekizumab (Taltz)events and moves- 11 Nov 2026 New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity own move +0.3%, next session -0.1%
- 5 Nov 2026 Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity own move -1.3%, next session -0.7%
- 9 Oct 2026 New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity own move -0.7%, next session -0.4%
- 31 Aug 2026 New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity own move -1.2%, next session -0.4%
- 28 Mar 2026 Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity own move +0.6%, next session +1.8%
- 18 Feb 2026 Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight own move -1.7%, next session +0.5%
- 8 Jan 2026 Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight own move -1.1%, next session -1.5%
| 7 | shown from 8 days |
Abemaciclib (Verzenio)events and moves- 13 Oct 2026 Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer own move -0.0%, next session +1.1%
- 12 Dec 2025 Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer own move +1.5%, next session +2.1%
- 24 Nov 2025 Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium own move +0.6%, next session +1.5%
- 17 Oct 2025 Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment own move -2.7%, next session -0.3%
- 13 Oct 2025 Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting own move -1.6%, next session -1.1%
- 27 Aug 2025 Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy own move -0.2%, next session +0.1%
- 11 Dec 2024 Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer own move +0.9%, next session -0.9%
| 7 | shown from 8 days |
mazdutideevents and moves- 14 Nov 2026 Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List own move -0.3%, next session +0.3%
- 25 Nov 2025 NMPA CDE accepts the mazdutide 9 mg supplementary application for review own move +1.5%, next session -0.3%
- 19 Nov 2025 GLORY-2 (NCT06164873) Phase 3 of mazdutide 9 mg met its primary and all key secondary endpoints own move +2.1%, next session -0.0%
- 26 Oct 2025 DREAMS-3 (NCT06184568) Phase 3 head-to-head versus semaglutide met its primary endpoint own move -0.1%, next session -0.1%
- 19 Sep 2025 NMPA approval: Glycemic control in adults with type 2 diabetes own move -1.3%, next session +0.9%
- 27 Jun 2025 NMPA approval: Chronic weight management in adults with overweight or obesity own move -2.3%, next session -0.1%
- 27 Jun 2025 Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management own move -2.3%, next session -0.1%
- 24 Jun 2025 Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions own move -0.3%, next session +1.7%
| 7 | shown from 8 days |
Tirzepatide (Zepbound) (Zepbound)events and moves- 14 Nov 2026 Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale own move -0.3%, next session +0.3%
- 11 Nov 2026 New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity own move +0.3%, next session -0.1%
- 28 May 2026 Foundayo and Zepbound now covered for millions of Americans own move +2.6%, next session -1.0%
- 12 May 2026 Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials own move +0.4%, next session +2.0%
- 29 Oct 2025 LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound own move +0.2%, next session +3.6%
- 27 Dec 2024 MHLW approval: Zepbound: obesity disease own move -0.9%, next session +0.0%
- 20 Dec 2024 FDA approves Zepbound for obstructive sleep apnea in adults with obesity own move +0.1%, next session +3.2%
- 20 Dec 2024 FDA approval: Zepbound: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity own move +0.1%, next session +3.2%
- 20 Dec 2024 FDA approval: Moderate to severe obstructive sleep apnea (OSA) in adults with obesity (Zepbound) own move +0.1%, next session +3.2%
| 7 | shown from 8 days |
Insulin Efsitora Alfa (Onswik)events and moves- 24 Sep 2026 U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes own move +2.1%, next session -0.4%
- 23 Sep 2026 FDA approval: type 2 diabetes mellitus. own move -1.0%, next session +2.1%
- 22 Jun 2025 Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials own move +1.4%, next session -0.3%
- 29 May 2025 Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions own move -0.2%, next session +1.9%
- 10 Sep 2024 Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes own move -1.2%, next session +2.5%
- 10 Sep 2024 With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes own move -1.2%, next session +2.5%
- 5 Sep 2024 In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin own move -2.2%, next session -0.8%
| 6 | shown from 8 days |
baricitinib (Olumiant)events and moves | 5 | shown from 8 days |
eloralintideevents and moves | 3 | shown from 8 days |
Selpercatinib (Retevmo)events and moves | 3 | shown from 8 days |
Sofetabart mipitecanevents and moves | 3 | shown from 8 days |
bimagrumabevents and moves | 2 | shown from 8 days |
EMP-01events and moves | 2 | shown from 8 days |
Olomorasibevents and moves | 2 | shown from 8 days |
Lepodisiranevents and moves | 1 | shown from 8 days |
Muvalaplinevents and moves | 1 | shown from 8 days |
VERVE-102events and moves | 1 | shown from 8 days |
BPL-003 (mebufotenin benzoate)events and moves | 1 | shown from 8 days |
VLS-01events and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 7% |
| Other company news (earnings, financing, releases naming no asset) | — | 30% |
| Sessions with no dated event | — | 23% |